Seth Pollack on Muck Rack

Seth Pollack

Seattle
As seen in: Nature, BMC Cancer, JAMA Oncology, SB Nation, Cell Reports Medicine, The Lancet, Cancer Epidemiology, Biomarkers & Prevention, NetsDaily, Golden State of Mind, Blazer's Edge and
Tech, photographer, climber, husband, father; co-founder of @RivalIQ; creator of @aviforecast
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Seth

Contact Seth, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

|
By Priscilla Merriam, James Morrow , Emanuele Mazzola, Nicole L. Solimini, Prafulla C. Gokhale, Ping Chi, Alice Chen, Mark Agulnik, Melissa Burgess, Scott M Schuetze, Neeta Somaiah, Brian Van Tine, Seth Pollack, Gabriel Tinoco, Jonathan C. Trent, Breelyn Wilky, Nicola Bothwick, Benjamin K. Eschle, Vivian Nguyen, Jan H. Beumer, Noushin Rastkari, Shahanawaz Jiwani, Peter Wu, Lorraine C. Pelosof, Matthew Hemming, Geoffrey I. Shapiro, George D. Demetri, Bradley E. Bernstein, Suzanne George
| Nature
Abstract While most gastrointestinal stromal tumors are driven by oncogenic mutations in KIT or PDGFRA, 10–15% exhibit functional loss of the succinate dehydrogenase (SDH) complex and genome-wide DNA hypermethylation. Excess methylation in SDH-deficient gastrointestinal stromal tumors disrupts genomic insulators, inducing aberrant expression of oncogenic ligands FGF3, FGF4, and activating an autocrine signaling loop mediated through FGFR1.
Open in Who Shared Issue with article?

Balancing Local Control With Long-Term Cosmesis in Re-Irradiation

|
By J. Isabelle Choi, Yan Leyfman, Seth Pollack
| ONCOLOGY journal
In the management of patients with locoregionally advanced breast cancer, the clinical mandate often shifts toward prioritizing local control, sometimes at the expense of long-term cosmesis. However, for survivors, the chronic sequelae of aggressive retreatment, particularly debilitating skin changes and fibrosis, can profoundly impact quality of life years after the final fraction is delivered. During the 2026 American College of Radiation Oncology (ACRO) Summit, CancerNetwork® sat down with J.
Open in Who Shared Issue with article?

CAR-T 2.0: Expanding Access, Speed, and Precision

|
By Yan Leyfman, Seth Pollack, Suzann Duan
| ONCOLOGY journal
Following the 2026 Tandem Meetings, Yan Leyfman, MD, from NewYork–Presbyterian Hospital and a hematologic malignancies board member for the journal ONCOLOGY®, outlined key advances that emerged from the conference. He noted that this year’s data reflect a critical transition from early proof-of-concept innovation to real-world refinement in safety, access, manufacturing, and durability of cellular therapies.
Open in Who Shared Issue with article?
See all 63 licensed articles (65 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Seth

Contact Seth, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified